FDA rejects cancer therapy for rare post-transplant disease
Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …
AI Summary: The FDA has again rejected Atara’s cell therapy aimed at treating rare post‐transplant complications linked to Epstein–Barr virus. Despite high hopes for this innovative approach, regulatory concerns remain over its safety and efficacy—clearly a “repeat performance” in the world of breakthrough therapies.
Related Stories
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
FDA makes one pivotal trial the default for drug approvals / 4 months
FDA refuses to review Moderna mRNA flu vaccine application / 5 months
Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 4 months
FDA clears first new sunscreen ingredient in two decades / 28 days
FDA commissioner Marty Makary resigns amid mounting scrutiny / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Obesity, Eli Lilly, None, Health Disparities and look for the RSS link.
StackHealth Time Machine